Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Семейная гиперхолестеринемия

Список литературы

  1. Близнюк С.А., Ежов М. ., Кухарчук В.В., Комар О.А. Гомозиготная семейная гиперхолестеринемия у молодой женщины: клинические проявления и современная терапия. Кардиологический вестник. 2016:11(1):74–78.
  2. Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю., Лукьянов М.М., Загребельный А.В., Гинзбург М.Л. Регистры в кардиологии. Основные правила проведения и реальные возможности. Кардиоваскулярная терапия и профилактика, 2013;12(1): 4-9.
  3. Диспансерное наблюдение больных хроническими неинфекционными заболеваниями и пациентов с высоким риском их развития. Методические рекомендации. Под ред. С.А. Бойцова и А.Г. Чучалина. — 112 с. Интернет-ресурс: http://www.gnicpm.ru, http://www.ropniz.ru.
  4. Ежов М.В., Сергиенко И.В., Рожкова Т.А., Кухарчук В.В., Коновалов Г.А., Мешков А.Н., Ершова А.И., Гуревич В.С., Константинов В.О., Соколов А.А., Щербакова М.Ю., Леонтьева И.В., Бажан С.С., Воевода М.И., Шапошник И.И. Российские рекомендации по диагностике и лечению семейной гиперхолестеринемии. Атеросклероз и дислипидемии. 2016;4:21–9.
  5. Ежов М.В., Сергиенко И.В., Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М., Бажан С.С., Балахонова Т.В., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галявич А.С., Горнякова Н.Б., Гуревич В.С., Драпкина О.М., Дупляков Д.В., Ерёгин С.Я., Зубарева М.Ю., Карпов Р.С., Карпов Ю.А., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачева Е.Д., Мартынов А.И., Небиеридзе Д.В., Покровский С.Н., Рагино Ю.И., Скибицкий В.В., Смоленская О.Г., Чазова И.Е., Шальнова С.А., Шапошник И.И., Кухарчук В.В. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации VI пересмотр. Атеросклероз и дислипидемии. 2017;3:5–22.
  6. Кухарчук В.В., Малышев П.П., Мешков А.Н. Семейная гиперхолестеринемия: современные аспекты диагностики, профилактики и терапии. Кардиология. 2009;49(1):76-83.
  7. Кухарчук В.В. Этиология и патогенез атеросклероза. Руководство по атеросклерозу и ишемической болезни сердца. Под ред. акад. Е.И. Чазова, член-корр. РАМН В.В. Кухарчука, проф. С.А. Бойцова. М.: Медиа Медика, 2007:736с.
  8. Кухарчук ВВ, Ежов МВ, Сергиенко ИВ, Арабидзе ГГ, Бубнова МГ, Балахонова ТВ, Гуревич ВС, Качковский МА, Коновалов ГА, Константинов ВО, Малышев ПП, Покровский СН, Соколов АА, Сумароков АБ, Горнякова НБ, Обрезан АГ, Шапошник ИИ. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии. 2020;1(38):7-42.
  9. Мандельштам, М. Ю., Васильев В.Б. Моногенные гиперхолестеринемии: новые гены, новые мишени для лечения. Генетика. 2008;44(10):1309-1316.
  10. Мешков А.Н., Малышев П.П., Кухарчук В.В.. Семейная гиперхолестеринемия в России: генетическая и фенотипическая характеристика. Терапевтический архив. 2009;81(9):23-8.
  11. Мешков А.Н., Ершова А.И., Деев А.Д., Метельская В.А., Жернакова Ю.В., Ротарь О.П., Шальнова С.А., Бойцов С.А. Распределение показателей липидного спектра мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012-2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62-67.
  12. Мешков В.Н., Ершова А.И., Щербакова Н.В., Рожкова Т.А., Калинина М.В., Кухарчук В.В., Бойцов С.А. Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутации генов LDLR и APOB. Кардиоваскулярная терапия и профилактика 2011;10(8):63—65.
  13. Мешков А.И., Ершова А.И., Щербакова Н.В., Рожкова Т.А., Калинина М.В., Малышев П.П., Кухарчук В.В., Бойцов С.А. Фенотипические особенности течения гетерозиготной формы семейной гиперхолестеринемии у носителей мутаций генов LDLR и APOB. Кардиоваскулярная терапия и профилактика 2011;10(8):63-65.
  14. Северин Е.С. Биохимия. Москва: Изд-во Гэотар-Медиа, 2008;768с.
  15. Шахтшнейдер Е.В., Иванощук Д.Е., Макаренкова К.В., Орлов П.С., Тимощенко О.В., Бажан С.С., Никитин Ю.П., Воевода М.И. Каскадный генетический скрининг в диагностике гетерозиготной формы семейной гиперхолестеринемии: клинический случай. Российский кардиологический журнал 2017;146(6):178–179.
  16. Шахтшнейдер Е.В., Макаренкова К.В., Астракова К.С., Иванощук Д.Е., Орлов П.С., Рагино Ю.И., Воевода М.И. Таргетное секвенирование гена PCSK9 у пациентов с семейной гиперхолестеринемией в России. Кардиология. 2017;57(6):46-51.
  17. Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derré A., Villéger L., Farnier M., Beucler I., Bruckert E., Chambaz J., Chanu B., Lecerf J.M., Luc G., Moulin P., Weissenbach J., Prat A., Krempf M., Junien C., Seidah N.G., Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003:34(2):154–156.
  18. Abifadel M, Rabès JP, Devillers M, Munnich A, Erlich D, Junien C, Varret M, Boileau C. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30(4):520-529.
  19. Austin M.A., Hutter C.M., Zimmern R.L., Humphries S.E. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160(5):407–420.
  20. Ahmad Z.S., Andersen R.L., Andersen L.H., O’Brien E.C., Kindt I., Shrader P., Vasandani C., Newman C.B., deGoma E.M., Baum S.J., Hemphill L.C., Hudgins L.C., Ahmed C.D., Kullo I.J., Gidding S.S., Duffy D., Neal W., Wilemon K., Roe M.T., Rader D.J., Ballantyne C.M., Linton M.F., Duell P.B., Shapiro M.D., Moriarty P.M., Knowles J.W. US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry. J Clin Lipidol. 2016;10:1223–1229.
  21. Athyros VG, Tziomalos K, Kakafika AI, Koumaras H, Karagiannis A, Mikhailidis DP. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483–485.
  22. Anedda S., Mura S., Marcello C., Pintus P. HELP LDL-apheresis in two cases of familial hypercholesterolemic pregnant women. Transfus. Apher. Sci. 2011;44(1):21-24.
  23. Antithrombotic Trialists’ Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849 –1860
  24. Brown M.S., Goldstein J.L. Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science. 1974: 185(4145):61–63. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 1989:232(4746):34–47.
  25. Brown L, Rosner B, WillettWW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30–42.
  26. Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008;29(1):11-2.
  27. Behesht S, Madse C, Varbo A, Nordestgaard B. Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects. J Am Coll Cardiol. 2020;75(20):2553-2566.
  28. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97(11):3956-64.
  29. Besseling J., Hovingh G.K., Huijgen R., Kastelein J.J., Hutten B.A. Statins in familial hypercholesterolemia: consequences for coronary artery disease and all-cause mortality. J Am Coll Cardiol. 2016;68(3):252–260.
  30. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 2014;64:485–494.
  31. Civeira F. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004;173(1):55-68.
  32. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., Kuivenhoven J.A., Nordestgaard B.G., Descamps O.S., Steinhagen-Thiessen E., Tybjærg-Hansen A., Watts G.F., Averna M., Boileau C., Bore´n J., Catapano A.L., Defesche J.C., Hovingh G.K., Humphries S.E., Kovanen P.T., Masana L., Pajukanta P., Parhofer K.G., Ray K.K., Stalenhoef A.F., Stroes E., Taskinen M.R., Wiegman A., Wiklund O., Chapman M.J. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J. 2014;35(32): 2146–2157.
  33. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670–1681.
  34. Coodley GO, Jorgensen M, Kirschenbaum J, Sparks C, Zeigler L, Albertson BD. Lowering LDL cholesterol in adults: a prospective, community-based practice initiative. Am J Med. 2008;121:604–10.
  35. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287 –1292.
  36. Cashin-Hemphill L., Noone M., Abbott J.F., Waksmonski C.A., Lees R.S. Low-density lipoprotein apheresis therapy during pregnancy. Am. J. Cardiol. 2000;86(10):1160.
  37. Clauss SB, Holmes KW, Hopkins P, Stein E, Cho M, Tate A, Johnson-Levonas AO, Kwiterovich PO. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116:682– 688.
  38. Cholesterol Treatment Trialists’ (CTT) Collaboration, Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397–1405
  39. Cannon CP, Blazing MA, Giugliano RP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med 2015;372:2387–97.
  40. Descamps OS, de Meester A, Cheron P, Kastelein JJ, Heller FR. Silent ischaemia in familial hypercholesterolemia. Atheroscler Suppl 2003;4:7–8.
  41. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years observations on male British doctors. BMJ 2004;328:1519.
  42. Ershova A.I., Meshkov A.N., Bazhan S.S., Storozhok M.A., Efanov A.Y., Medvedeva I.V., Indukaeva E.V., Danilchenko Y.V., Kuzmina O.K., Barbarash O.L., Deev A.D., Shalnova S.A., Boytsov S.A. The prevalence of familial hypercholesterolemia in the West Siberian region of the Russian Federation: A substudy of the ESSE-RF. PLoS One. 2017;12(7):e0181148.
  43. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L,Pinto X, Basora J, Munoz MA, Sorlı JV, Martınez JA, Martınez-Gonzalez MA. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279–1290.
  44. Eapen DJ, Valiani K, Reddy S, Sperling L. Management of familial hypercholesterolemia during pregnancy: case series and discussion. J Clin Lipidol. 2012;6(1):88-91.
  45. Ertorer M.E., Guvenc B., Haydardedeoglu B., Tekinturhan F. A case report of the cascade filtration system: a safe and effective method for low-density lipoprotein apheresis during pregnancy. Ther. Apher Dial. 2008;12(5):396-400.
  46. EAS Familial Hypercholesterolaemia Studies Collaboration. Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. Atheroscler Suppl. 2016;22:1-32.
  47. Familial Hypercholesterolemia: Results of the Phase 3 Extension Trial. Journal of Clinical Lipidology. 2016;10(3):708–710.
  48. Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in heterozygous familial hypercholesterolaemia or high CV risk populations: Pooled analyses of eight phase 3 trials. Atherosclerosis. 2015;241:e25–e26.
  49. Goldstein J.L, Brown M.S. Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of . Proc Natl Acad Sci U S A. 1973: 70: 2084–2088.
  50. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. In: The Metabolic and Molecular Bases of Inherited Disease 8th ed. Goldstein J.L. New York: McGraw-Hill 2001:2863–2914.
  51. Gray J., Jaiyeola A., Whiting M., Modell M., Wierzbicki A.S. Identifying patients withfamilial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart. 2008;94(6):754–758.
  52. Gandelman K, Glue P, Laskey R, Jones J, LaBadie R, Ose L. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. Pediatr Cardiol. 2011;32(4):433-41.
  53. Gordon B.R., Kelsey S.F., Dau P.C., Gotto A.M. Jr., Graham K., Illingworth D.R., Isaacsohn J., Jones P.H., Leitman S.F., Saal S.D., Stein E.A., Stern T.N., Troendle A., Zwiener R.J. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am. J. Cardiol. 1998;81(4):407-411.
  54. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469–2475.
  55. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962-1971.
  56. Ginsberg H.N., Rader D.J., Raal F.J., Guyton J.R., Baccara-Dinet M.T., Lorenzato C., Pordy R., Stroes E. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. Cardiovasc Drugs Ther. 2016;30(5): 473–483.
  57. Hopkins PN, Toth PP, Ballantyne CM, Rader DJ Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on FamilialHypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S9-17.
  58. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133–170.
  59. Hopkins P.N., Defesche J., Fouchier S.W., Bruckert E., Luc G., Cariou B., Sjouke B., Leren T.P., Harada-Shiba M., Mabuchi H., Rabès J.P., Carrié A., van Heyningen C., Carreau V., Farnier M., Teoh Y.P., Bourbon M., Kawashiri M.A., Nohara A., Soran H., Marais A.D., Tada H., Abifadel M., Boileau C., Chanu B., Katsuda S., Kishimoto I., Lambert G., Makino H., Miyamoto Y., Pichelin M., Yagi K., Yamagishi M., Zair Y., Mellis S., Yancopoulos G.D., Stahl N., Mendoza J., Du Y., Hamon S., Krempf M., Swergold G.D. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet. 2015;8(6):823–831.
  60. Harada-Shiba M., Takagi A., Miyamoto Y., Tsushima M., Ikeda Y., Yokoyama S., Yamamoto A. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab. 2003;88(6):2541-2547.
  61. Hovingh G.K., Davidson M.H., Kastelein J.J., O’Connor A.M. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J. 2013;34(13):962–971.
  62. Humphries SE, Cranston T, Allen M, Middleton-Price H, Fernandez MC, Senior V, Hawe E, Iversen A, Wray R, Crook MA,Wierzbicki AS. Mutational analysis in UK patients with a clinical diagnosis of familialhypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J Mol Med (Berl). 2006;84(3):203-14.
  63. Hollaender PL, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. Am J Clin Nutr 2015;102:556–572.
  64. Hagger MS, Hardcastle SJ, Hingley C, Strickland E, Pang J, Watts GF. Predicting Self-Management Behaviors in Familial Hypercholesterolemia Using an Integrated Theoretical Model: the Impact of Beliefs About Illnesses and Beliefs About Behaviors. Int J Behav Med. 2016;23(3):282-294.
  65. Hovingh GK, Raal FJ, Dent R, Stefanutti C, Descamps O, Masana L, Lira A, Bridges I, Coll B, Sullivan D. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(6):1448-1457.
  66. Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2010;17:667–74.
  67. Hohenstein B., Julius U., Lansberg P., Jaeger B., Mellwig K.P., Weiss N., et al. Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes. Atheroscler. Suppl. 2017;30:180-186.
  68. Heigl F., Hettich R., Lotz N., Reeg H., Pflederer T., Osterkorn D., et al. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL-or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler. Suppl. 2015;18:154-162.
  69. Innerarity T.L., Weisgraber K.H., Arnold K.S, Mahley R.W., Krauss R.M., Vega G.L., Grundy S.M. Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proceedings of the National Academy of Sciences of the United States of America. 1987;84(19):6919–6923.
  70. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, Kastelein JJ. The contribution of classical risk factorsto cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004;256:482–490.
  71. Jongh S, Ose L, Szamosi T, Gagne C, Lambert M, Scott R, Perron P, Dobbelaere D, Saborio M, Tuohy MB, Stepanavage M, Sapre A, Gumbiner B, Mercuri M, van Trotsenburg AS, Bakker HD, Kastelein JJ. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106:2231–2237.
  72. Khachadurian A.K. The inheritance of essential familial hypercholesterolemia. Am J Med. 1964:37:402-407.
  73. Klančar G., Grošelj U., Kovač J., Bratanič N., Bratina N., Trebušak Podkrajšek K., Battelino T. Universal Screening for Familial Hypercholesterolemia in Children. J Am Coll Cardiol. 2015;66(11):1250–1257.
  74. Keys A. Serum cholesterol response to dietary cholesterol. Am J Clin Nutr 1984;40:351–359.
  75. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: another look at a meta-analysis using prediction intervals. Prev Med 2009;49:473–475.
  76. Kastelein J.J., Akdim F., Stroes E.S., Zwinderman A.H., Bots M.L., Stalenhoef A.F., Visseren F.L., Sijbrands E.J., Trip M.D., Stein E.A., Gaudet D., Duivenvoorden R., Veltri E.P., Marais A.D., de Groot E. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med. 2008;358(14):1431–1443.
  77. Kastelein J.J., Ginsberg H.N., Langslet G., Hovingh G.K., Ceska R., Dufour R., Blom D., Civeira F., Krempf M., Lorenzato C., Zhao J., Pordy R., Baccara-Dinet M.T., Gipe D.A., Geiger M.J., Farnier M. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36(43):2996–3003.
  78. Kastelein J.J., Hovingh G.K., Langslet G., Baccara-Dinet M.T., Gipe D.A., Chaudhari U., Zhao J., Minini P., Farnier
    M. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs
    placebo in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2017;11(1):195–203.
  79. Knipscheer HC, Boelen CC, Kastelein JJ, van Diermen DE, Groenemeijer BE, van den Ende A, Buller HR, Bakker HD. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res. 1996;39:867– 871.
  80. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl. 2009;10(5):21-26.
  81. Kitano Y., Thompson G.R. The familial hypercholesterolemia regression study: a randomized comparison of therapeutic reduction of both low-density lipoprotein and lipoprotein(a) versus low-density lipoprotein alone. Ther. Apher. 1997;1(2):187-190.
  82. Klingel R., Heibges A., Fassbender C., ProLiFe-Study G. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines // Clin. Res. Cardiol. Suppl. 2017:12(1):38-43.
  83. Khan T.Z., Hsu L.Y., Arai A.E., Rhodes S., Pottle A., Wage R., et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. Eur. Heart. J. 2017;38(20):1561-1569.
  84. Lambert G., Sjouke B., Choque B., Kastelein J.J., Hovingh G.K. The PCSK9 decade. J Lipid Res. 2012;53(12):2515– 2524.
  85. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340–2346.
  86. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403-25.
  87. Landmesser U., Chapman M.J., Stock J.K., Amarenco P., Belch J.J., Borén J., Farnier M., Ference B.A., Gielen S., Graham I., Grobbee D.E., Hovingh G.K., Lüscher T.F., Piepoli M.F., Ray K.K., Stroes E.S., Wiklund O., Windecker S., Zamorano J.L., Pinto F., Tokgözoglu L., Bax J.J., Catapano A.L. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018;39(14):1131–1143.
  88. Melendez Q.M., Krishnaji S.T., Wooten C.J., Lopez D. Hypercholesterolemia: The role of PCSK9. Archives of biochemistry and biophysics. 2017;625:39–53.
  89. Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993;104(1-2):1–18.
  90. Merino-Ibarra E, Castillo S, Mozas P, Cenarro A, Martorell E, Díaz JL, Suárez-Tembra M, Alonso R, Civeira F, Mata P, Pocoví M. Screening of APOB gene mutations in subjects with clinical diagnosis of familialhypercholesterolemia. Hum Biol. 2005 ;77(5):663-73.
  91. Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O; ESC Scientific Document Group. 2019ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J.2020;41(1):111-188.
  92. Maxwell KN, Fisher EA, Breslow JL. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc Natl Acad Sci U S A. 2005;102(6):2069-74.
  93. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52: 1769–1781.
  94. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group. 2019ESC/EAS Guidelines for the management of dyslipidemias:lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1):111-188.
  95. Michaelides AP, Fourlas CA, Pitsavos C, Andrikopoulos GK, Skoumas I, Kartalis A, Katsaros A, Stougiannos P, Stefanadis CI. Exercise testing in asymptomatic patients with heterozygous familial hypercholesterolaemia. Coron Artery Dis. 2004;15(8):461-5.
  96. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003;37:283–290.
  97. Montalescot G., Sechtem U., Achenbach S.et al. «2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable Coronary artery disease of European Society of Cardiology». Eur Heart J 2013; 34, 2949-3003.
  98. Mozaffarian D, Micha R,Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Med 2010;7:e1000252.
  99. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr 2009;63(Suppl 2):S5–S21.
  100. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother 2012;10:264 –271.
  101. Mata N, Alonso R, Banegas JR, Zambón D, Brea A, Mata P. Quality of life in a cohort of familial hypercholesterolemia patients from the south of Europe. Eur J Public Health. 2014;24(2):221-5.
  102. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143:74 – 80.
  103. Moriarty PM et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statinrechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758-769.
  104. Marteau T, Senior V, Humphries SE, Bobrow M, Cranston T, Crook MA, Day L, Fernandez M, Horne R, Iversen A, Jackson Z, Lynas J, Middleton-Price H, Savine R, Sikorski J, Watson M, Weinman J, Wierzbicki AS, Wray R. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: a randomized controlled trial. Am J Med Genet A. 2004;128A(3):285-93.
  105. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;52: 1769–1781.
  106. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., Wiegman A., Santos R.D., Watts G.F., Parhofer K.G., Hovingh G.K., Kovanen P.T., Boileau C., Averna M., Borén J., Bruckert E., Catapano A.L., Kuivenhoven J.A., Pajukanta P., Ray K., Stalenhoef A.F., Stroes E., Taskinen M.R., Tybjærg-Hansen A. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478–3490.
  107. Neil H.A., Hawkins M.M., Durrington P.N., Betteridge D.J., Capps N.E., Humphries S.E: Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study. Atherosclerosis. 2005;179(2):293–297.
  108. National Institute for Health and Clinical Excellence. Familial hypercholesterolemia: identification and management. NICE publishes updated familial hypercholesterolaemia guidance. Br J Cardiol. 2017;24:129.
  109. Nissen SE et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315(15):1580-90.
  110. Ouguerram K, Chetiveaux M, Zair Y, Costet P, Abifadel M, Varret M, Boileau C, Magot T, Krempf M. Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9. Arterioscler Thromb Vasc Biol. 2004;24(8):1448-53.
  111. Pérez de Isla L., Alonso R., Mata N., Saltijeral A., Muñiz O., Rubio-Marin P., Diaz-Diaz J.L., Fuentes F., de Andrés R., Zambón D., Galiana J., Piedecausa M., Aguado R., Mosquera D., Vidal J.I., Ruiz E., Manjón L., Mauri M., Padró T., Miramontes-González J.P., Mata P. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 2016;36(9):2004–2010.
  112. Pereira C, Miname M, Makdisse M, Kalil Filho R, Santos RD. Association of peripheral arterial and cardiovascular diseases in familial hypercholesterolemia. Arq Bras Cardiol. 2014 Aug;103(2):118-23. Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O, Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 2016;36(9):2004-10.
  113. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998;316: 1043–1047.
  114. Pokrovsky S.N., Afanasieva O.I., Safarova M.S., Balakhonova T.V., Matchin Yu.G., Adamova I.Yu., Konovalov G.A., Ezhov M.V. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity. Atheroscler. Suppl. 2017;30:166-173.
  115. Raal F.J., Stein E.A., Dufour R., Turner T., Civeira F., Burgess L., Langslet G., Scott R., Olsson A.G., Sullivan D., Hovingh G.K., Cariou B., Gouni-Berthold I., Somaratne R., Bridges I., Scott R., Wasserman S.M., Gaudet D. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331–340.
  116. Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Xu F, Scott R, Wasserman SM, Stein EA; TESLAInvestigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):341-350. Clin Genet. 2010;77(6):572-580.
  117. Raal FJ, Hovingh GK, Blom D et al. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol. 2017;5(4):280-290.
  118. Raal FJ, Kallend D, Ray KK, Turner T, Koenig W, Wright RS, Wijngaard PLJ, Curcio D, Jaros MJ, Leiter LA, Kastelein JJP; ORION-9 Investigators. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med. 2020; 382:1520-1530.
  119. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, Kastelein JJP; ORION-10 and ORION-11 Investigators. Two phase 3 trials of Inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507-1519.
  120. Rodenburg J, Vissers MN, Wiegman A, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116:664–8.
  121. Südhof T.C., Goldstein J.L., Brown M.S., Russell D.W. The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 2018;228(4701):815–822.
  122. Soutar A.K., Naoumova R.P. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214–225.
  123. Soufi M, Sattler AM, Maerz W, Starke A, Herzum M, Maisch B, Schaefer JR. A new but frequent mutation of apoB-100-apoB His3543Tyr. Atherosclerosis. 2004;74(1):11.
  124. Sharifi M, Futema M, Nair D, Humphries SE. Genetic Architecture of Familial Hypercholesterolaemia. Curr Cardiol Rep. 2017;19(5):44.
  125. Sijbrands EJ, Westendorp RG, Paola Lombardi M, Havekes LM, Frants RR, Kastelein JJ, Smelt AH. Additional risk factors influence excess mortality in heterozygous familial hypercholesterolaemia. Atherosclerosis. 2000;149(2):421-5.
  126. Sjouke B.D., Kusters M., Kindt I., Besseling J., Defesche J.C., Sijbrands E.J., Roeters van Lennep J.E., Stalenhoef A.F., Wiegman A., de Graaf J., Fouchier S.W., Kastelein J.J., Hovingh G.K. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome. Eur Heart J. 2014;36(9):560–565.
  127. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet. 1969;2(7635):1380-2.
  128. Santos R.D., Gidding S., Hegele R.A., Cuchel M.A., Barter P.J., Watts G.F., Baum S.J., Catapano A.L., Chapman M.J., Defesche J.C., Folco E., Freiberger T., Genest J., Hovingh G.K., Haradashiba M., Humphries S.E., Jackson A.S., Mata P., Moriarty P.M., Raal F.J., Alrasidi K., Ray K.K., Reiner Z., Sijbrands E.J., Yamashita S. International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel: Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016; 4(10):850–861.
  129. Shaw K, Gennat H, O’Rourke P, Del Mar C. Exercise for overweight or obesity. Cochrane Database Syst Rev 2006;4:CD003817.
  130. Smilde T.J., Wissen V.S., Wollersheim H., Trip M.D., Kastelein J.J., Stalenhoef A.F. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 2001;357(9256):577–581.
  131. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR. Efficacy and tolerability of Fluvastatin XL 80 mg alone, ezetimibe alone and the combination of Fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins: a randomized, doubleblind, double-dummy trial. Am J Cardiol 2008;101:490–496.
  132. Stroes E, Colquhoun D, Sullivan D et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014 Jun 17;63(23):2541-2548.
  133. Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999;281: 137–144.
  134. Stefanutti C., Vivenzio A., S. Giacomo S.D., Mazzarella B., Bosco G., Berni A. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion. 2009;49(7):1461–1470.
  135. Schatz U., Tselmin S., Muller G., Julius U., Hohenstein B., Fischer S., et al. Most significant reduction of cardiovascular events in patients undergoing lipoproteinapheresis due to raised Lp(a) levels - A multicenter observational study. Atheroscler. Suppl. – 2017;30: 246-252.
  136. Safarova M.S., Ezhov M.V., Afanasieva O.I., Matchin Yu.G., Atanesyan R.V., Adamova I.Yu., Utkina E.A., Konovalov G.A., Pokrovsky S.N. Effect of specific Lp(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 2013;14:93-99.
  137. Taylor A., Wang D., Patel K., Whittall R., Wood G., Farrer M., Neely R.D., Fairgrieve S., Nair D., Barbir M., Jones J.L., Egan S., Everdale R., Lolin Y., Hughes E., Cooper J.A., Hadfield S.G., Norbury G., Humphries S.E. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project.
  138. Thompson G.R., Seed M., Niththyananthan S., McCarthy S., Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis. 1989;9(1):75–80.
  139. Sharifi M, Rakhit RD, Humphries SE, Nair D. Cardiovascular risk stratification in familial hypercholesterolaemia. Heart. 2016;102(13):1003-8.
  140. Thompson G.R., Lowenthal R., Myant N.B. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1(7918):1208–1211.
  141. Thompson G.R. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular diseases. Atheroscler. Suppl. 2013;14(1):67-70.
  142. Tatami R., Inoue N., Itoh H., Kishino B., Koga N., Nakashima Y., Nishide T., Okamura K., Saito Y., Teramoto T. Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators. Atherosclerosis. 1992;95(1):1-13.
  143. Tyroler HA. Cholesterol and cardiovascular disease. An overview of Lipid Research Clinics (LRC) epidemiologic studies as background for the LRC Coronary Primary Prevention Trial. Am J Cardiol 1984;54:14C–19C.
  144. Vega G.L., Grundy S.M. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest. 1986:78:1410–1414.
  145. Vuorio A, Doherty KF, Humphries SE, Kuoppala J, Kovanen PT. Statin treatment of children with familial hypercholesterolemia — trying to balance incomplete evidence of long-term safety and clinical accountability: are we approaching a consensus? Atherosclerosis 2013;226:315–20.
  146. Versmissen J, Oosterveer DM, Yazdanpanah M, Defesche JC, Basart DC, Liem AH, Heeringa J, Witteman JC, Lansberg PJ, Kastelein JJ, Sijbrands EJ. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008;337:a2423.
  147. van der Graaf A, Avis HJ, Kusters DM, Vissers MN, Hutten BA, Defesche JC, Huijgen R, Fouchier SW, Wijburg FA, Kastelein JJ, Wiegman A. Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation 2011;123:1167–1173.
  148. Wilkinson C.E., Hand E.A., Fliegelman M.T. Essential familial hypercholesterolemia. Ann Intern Med. 1948; 29:671.
  149. Widhalm K, Dirisamer A, Lindemayr A, Kostner G. Diagnosis of families with familial hypercholesterolaemia and/or Apo B-100 defect by means of DNA analysis of LDL-receptor gene mutations. J Inherit Metab Dis. 2007;30(2):239-47.
  150. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjærg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437.
  151. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Bu¨ller HR, Sijbrands EJ, Kastelein JJ. Efficacy and safety of statin therapy in Rodenburg et al Statin Treatment in Children with familial hypercholesterolemia: a randomized controlled trial. JAMA. 2004;292:331–337.
  152. Wiegman A, de Groot E, Hutten BA, Rodenburg J, Gort J, Bakker HD, Sijbrands EJ, Kastelein JJ. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;363(9406):369-70.
  153. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 2007; 335:599.
  154. Wang N, Tall AR. New approach to PCSK9 therapeutics. N Engl J Med 2017; 376:41-51.
  155. Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L., Goldstein J.L., Russell D.W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984;39(1):27–38.
  156. Yuan G, Wang J, Hegele RA. Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ. 2006;174(8):1124-9.
  157. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program’s Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. Am J Clin Nutr 1999;69: 632–646.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу